Can-Fite BioPharma Ltd. (NYSE American: CANF) isanadvanced clinical stage drug development company with a novel therapeutic approach for the treatment of liver and inflammatory diseases, addressing multi-billion dollar markets.
Oral drugs with proven safety and efficacy – Piclidenoson and Namodenoson are Phase III assets in psoriasis and liver cancer and Namodenoson showed strong efficacy in a Phase II NASH study. Piclidenoson has recently been approved by FDA and IRBs to commence enrollment of patients with moderate COVID-19 in a Phase II study.
Intellectual property portfolio – consists of 15 patent families issued and pending.
Corporate partnerships – Piclidenoson and Namodenoson have been out-licensed in select territories with ~$18 million received to date.
Financially well positioned – the company is well positioned to conduct all its clinical development programs and G&A for > 1 year
For further details on Benzinga’s Global Small Cap Conference and other events, visit https://www.benzinga.com/events/small-cap/
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, covers dozens of investor conferences and online events as part of its ongoing service to the investment community. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of each featured session.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its many event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com